GlassScriptPhysician profile
Sagar Desai
NPI 1386649861
$11,793.36
in general payments reported to CMS, 2019-2025
44 companies · $2,306 in 2025
The $2,306 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,228 · 2020: $1,262 · 2021: $1,589 · 2022: $2,022 · 2023: $1,037 · 2024: $2,350 · 2025: $2,306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,692.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,714.57 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,364.40 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $801.82 | 2022-2025 | |
| Penumbra, INC. | $796.48 | 2024-2025 | Indigo System, Penumbra System |
| Lilly USA, LLC | $712.11 | 2019-2025 | Mounjaro, Kisunla, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $670.44 | 2019-2025 | Jardiance |
| Abbvie INC. | $578.45 | 2021-2025 | Ubrelvy, Linzess, Viberzi |
| Arthrex, INC. | $575.51 | 2022 | |
| Abbott Laboratories | $512.01 | 2020-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $411.48 | 2019-2024 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $401.28 | 2019-2021 | |
| Amgen INC. | $391.77 | 2020-2025 | Otezla, Repatha, Repatha |
| Genzyme Corporation | $248.31 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $222.89 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $217.07 | 2022-2025 | Xifaxan, Trulance |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sagar Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.